PMID- 23714666
OWN - NLM
STAT- MEDLINE
DCOM- 20131031
LR  - 20181023
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 35
IP  - 2
DP  - 2013 Feb
TI  - [Significance of myc gene rearrangement and its correlation with prognosis in 
      diffuse large B cell lymphoma].
PG  - 119-23
LID - 10.3760/cma.j.issn.0253-3766.2013.02.009 [doi]
AB  - OBJECTIVE: To study the relationship between myc gene rearrangement and myc 
      protein expression in diffuse large B cell lymphoma (DLBCL), and their 
      correlation with prognosis. METHODS: One hundred and six cases of DLBCLs with 
      follow-up data were analyzed using interphase fluorescence in situ hybridization 
      (FISH) technique. Immunophenotyping analysis for CD20, CD3, myc, Mum-1, CD10, 
      bcl-6 was also performed using EnVision immunohistochemistry. RESULTS: The 
      percentages of tumor cells expressing myc, Mum-1, CD10 and bcl-6 were 70.8%, 
      56.6%, 21.7% and 26.4%, respectively. Twenty six cases (24.5%) were of GCB type 
      and the rest (75.5%) were of non-GCB (non germinal center) type. The myc 
      rearrangement was identified in 13 (12.3%) of 106 cases. 13 cases showed to be of 
      non-GCB type. There was no correlation between myc rearrangement and myc protein 
      expression. DLBCLs (n = 13) with myc rearrangement showed significantly poorer 
      overall survival (OS) and progression free survival (PFS), with a median OS and 
      PFS time of 4.7 and 3.2 months, respectively (for OS and PFS, P < 0.001). 
      Multivariate analysis using Cox proportional hazard model confirmed that myc 
      rearrangement, ECOG performance status of 2-4, immunophenotyping subgroup and myc 
      protein were independent factors affecting the prognosis and significantly 
      associated with the survival. However, myc rearrangement was the strongest 
      prognostic factor. CONCLUSIONS: DLBCL with myc gene rearrangement is a subgroup 
      of non-GCB DLBCL with poor outcome. It is an independent and useful factor for 
      prognosis in DLBCL. Expression of myc is influenced by many factors and myc 
      rearrangement may be one of these factors.
FAU - Zhang, Hong-wei
AU  - Zhang HW
AD  - Department of Hematology, Shanxi Tumor Hospital, Taiyuan, China.
FAU - Chen, Zhen-wen
AU  - Chen ZW
FAU - He, Jian-xia
AU  - He JX
FAU - Zheng, Yu-ping
AU  - Zheng YP
FAU - Han, Wei-e
AU  - Han WE
FAU - Zhao, Zhi-qiang
AU  - Zhao ZQ
FAU - Bai, Wei
AU  - Bai W
FAU - Wang, Jin-fen
AU  - Wang JF
LA  - chi
PT  - English Abstract
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Interferon Regulatory Factors)
RN  - 0 (Proto-Oncogene Proteins c-bcl-6)
RN  - 0 (Proto-Oncogene Proteins c-myc)
RN  - 0 (interferon regulatory factor-4)
RN  - 5J49Q6B70F (Vincristine)
RN  - 80168379AG (Doxorubicin)
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - EC 3.4.24.11 (Neprilysin)
RN  - VB0R961HZT (Prednisone)
RN  - CHOP protocol
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cyclophosphamide/therapeutic use
MH  - Disease-Free Survival
MH  - Doxorubicin/therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - *Gene Rearrangement, B-Lymphocyte
MH  - *Genes, myc
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Interferon Regulatory Factors/metabolism
MH  - Lymphoma, Large B-Cell, Diffuse/drug therapy/*genetics/metabolism/pathology
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Neprilysin/metabolism
MH  - Prednisone/therapeutic use
MH  - Proportional Hazards Models
MH  - Proto-Oncogene Proteins c-bcl-6/metabolism
MH  - Proto-Oncogene Proteins c-myc/*metabolism
MH  - Survival Rate
MH  - Vincristine/therapeutic use
EDAT- 2013/05/30 06:00
MHDA- 2013/11/01 06:00
CRDT- 2013/05/30 06:00
PHST- 2013/05/30 06:00 [entrez]
PHST- 2013/05/30 06:00 [pubmed]
PHST- 2013/11/01 06:00 [medline]
AID - 10.3760/cma.j.issn.0253-3766.2013.02.009 [doi]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2013 Feb;35(2):119-23. doi: 
      10.3760/cma.j.issn.0253-3766.2013.02.009.